Novartis Price to Earning

NVS -- USA Stock  

USD 84.44  0.53  0.63%

The Macroaxis Fundamental Analysis lookup allows users to check a given indicator for any equity or select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools

Novartis Price to Earning Analysis

Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investor monitor on a daily basis. Holding a low PE stock is less risky because. When a company's profitability fall, it is likely that earnings will also go down..In other words, if you start from a lower position your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Market Value Per Share 
Earnings Per Share 
More About Price to Earning | All Equity Analysis
Novartis Price to Earning  =
Novartis ValuationFundamentalsBuy or Sell

Price to Earning Over Time Pattern

 Novartis Price to Earnings Ratio 

About Price to Earning

Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Compare to competition

Novartis Price to Earning Assessment

Earning Before Interest and Taxes EBIT
Based on latest financial disclosure the price to earning indicator of Novartis AG is roughly 15.68 times. This is 39.32% lower than that of the Healthcare sector, and 66.1% lower than that of Drug Manufacturers - Major industry, The Price to Earning for all stocks is 45.4% higher than the company.

Did you try this?

Run Price Ceiling Movement Now


Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
All  Next Launch Module

Novartis current financial ratios